Insulet (NASDAQ:PODD) Price Target Raised to $234.00

Insulet (NASDAQ:PODD) had its target price upped by Barclays from $220.00 to $234.00 in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has an equal weight rating on the medical instruments supplier’s stock.

Other equities analysts have also recently issued reports about the company. Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock. BTIG Research boosted their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Canaccord Genuity Group increased their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Citigroup boosted their target price on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Finally, Piper Sandler increased their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Performance

PODD stock opened at $269.06 on Monday. The stock has a market capitalization of $18.87 billion, a PE ratio of 46.07, a price-to-earnings-growth ratio of 4.26 and a beta of 1.22. The stock’s 50 day simple moving average is $235.96 and its 200 day simple moving average is $206.47. Insulet has a 12-month low of $160.19 and a 12-month high of $279.40. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Blue Trust Inc. raised its position in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the period. Venturi Wealth Management LLC lifted its stake in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Insulet in the 2nd quarter valued at about $32,000. UMB Bank n.a. increased its stake in Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares in the last quarter. Finally, CVA Family Office LLC raised its holdings in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.